Status:
TERMINATED
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Brain Neoplasms
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC
Eligibility Criteria
Inclusion
- Radiologically confirmed brain metastases from Non Small Cell Lung Cancer
- No symptoms due to brain metastases
- No previous radiotherapy treatment for the Brain metastases
Exclusion
- No prior chemotherapy
- No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
- Any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00234442
Start Date
July 1 2004
End Date
February 1 2006
Last Update
June 30 2009
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Bologna, Italy
2
Research Site
Orbassano, Italy
3
Research Site
Parma, Italy
4
Research Site
Rozzano, Italy